Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HFA-152a
HFA-152a, HFA-134a, Radiolabeled saline · 2 trials · 1 indication
\[AUC(0-4h)\] was assessed for Mucociliary clearance (MCC) in participants following administration of nebulized 99mTc on Day 7. Gamma scintigraphy was utilized to conduct assessments.
| Arm | Type | Description |
|---|---|---|
| Participants receiving HFA-152a followed by HFA-134a | EXPERIMENTAL | Participants will receive HFA-152a MDI in treatment period 1 followed by HFA-134a MDI in treatment period 2. There will be a washout period between the treatment periods. |
| Participants receiving HFA-134a followed by HFA-152a | EXPERIMENTAL | Participants will receive HFA-134a MDI in treatment period 1 followed by HFA-152a MDI in treatment period 2. There will be a washout period between the treatment periods. |
| HFA-152a followed by HFA-134a | EXPERIMENTAL | - |
| HFA-134a followed by HFA-152a | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HFA-152a | DRUG | HFA-152a will be administered. |
| HFA-134a | DRUG | HFA-134a will be administered. |
| Radiolabeled saline solution | OTHER | Radiolabeled saline solution is administered via oral inhalation |
Inclusion Criteria: * Participant must be aged greater than equal to (\>=)18 years at the time of signing the informed consent. * Participants with asthma for \>= 6 months, defined as: * Documented history of asthma, as defined by Global Initiative for Asthma (GINA) * Receiving one of following ...
HFA-152a is an investigational propellant being studied for use in asthma inhalers. It is being evaluated in clinical trials to compare its safety and effects with HFA-134a, another propellant, in patients with asthma. The drug is currently in Phase 3 clinical development.
HFA-152a does not target a specific molecular receptor or pathway. It is a propellant, a substance used to deliver medication from an inhaler. Its role is to help aerosolize the asthma medication for inhalation, rather than to act on a biological target in the body.
HFA-152a is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of this propellant for use in asthma inhalers.
HFA-152a is in Phase 3 clinical development. One Phase 3 trial, NCT07645248, is planned to compare the safety of four weeks of exposure to HFA-152a and HFA-134a in patients with asthma. A Phase 1 trial has already been completed.
HFA-152a has been studied in two clinical trials. NCT06506266, a completed Phase 1 study, examined the effect of HFA-152a and HFA-134a on mucociliary clearance in healthy participants. NCT07645248, a Phase 3 trial not yet recruiting, will compare the safety of four weeks of exposure to the two propellants in asthma patients.
No, HFA-152a is not the same as HFA-134a. They are different propellants: HFA-152a is 1,1-difluoroethane, while HFA-134a is 1,1,1,2-tetrafluoroethane. GSK is studying HFA-152a as a potential alternative to HFA-134a in asthma inhalers, and trials are comparing their safety and effects.